secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K/A
Filed at:   2024-03-14T23:59:59+00:00
Accession:  0001193805-24-000364
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus Therapeutics amends FY2023 results: revenue down $3.2M, net loss wider
-------------------------------------------------------------------------------

- Collaboration revenue for FY2023 decreased from $160.9M to $157.7M; Q4 2023 from $28.2M to $25.0M.
- Updated net loss: FY2023 $29.7M ($1.12 per share); Q4 2023 $11.7M ($0.44 per share).
- Adjustments are non-cash: deferred revenue increased $3.2M, offset by reduction in stockholders' equity.
- Cash, equivalents, restricted cash and cash runway unchanged.
- Annual Report on Form 10-K for FY2023 filed March 14, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380524000364/0001193805-24-000364-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380524000364/e619365_8ka-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-24-000364

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer